Clinical Trial Update: A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the safety, tolerability and efficacy of E7070 in patients with renal cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• E7070

Snippet

Sponsor: Eisai Inc. | Conditions: Kidney Neoplasms, Carcinoma, Renal Cell | Phase 2 | Status: COMPLETED